ES2465478T8 - Composiciones farmacéuticas que comprenden brivaracetam - Google Patents

Composiciones farmacéuticas que comprenden brivaracetam Download PDF

Info

Publication number
ES2465478T8
ES2465478T8 ES09753941.5T ES09753941T ES2465478T8 ES 2465478 T8 ES2465478 T8 ES 2465478T8 ES 09753941 T ES09753941 T ES 09753941T ES 2465478 T8 ES2465478 T8 ES 2465478T8
Authority
ES
Spain
Prior art keywords
brivaracetam
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09753941.5T
Other languages
English (en)
Other versions
ES2465478T3 (es
Inventor
Frédéric EECKMAN
Monique Berwaer
Domenico Fanara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39714168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2465478(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of ES2465478T3 publication Critical patent/ES2465478T3/es
Publication of ES2465478T8 publication Critical patent/ES2465478T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09753941.5T 2008-05-30 2009-05-28 Composiciones farmacéuticas que comprenden brivaracetam Active ES2465478T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08009919 2008-05-30
EP08009919 2008-05-30
PCT/EP2009/056570 WO2009144286A1 (en) 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam

Publications (2)

Publication Number Publication Date
ES2465478T3 ES2465478T3 (es) 2014-06-05
ES2465478T8 true ES2465478T8 (es) 2014-08-22

Family

ID=39714168

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09753941.5T Active ES2465478T3 (es) 2008-05-30 2009-05-28 Composiciones farmacéuticas que comprenden brivaracetam

Country Status (10)

Country Link
US (1) US8435564B2 (es)
EP (1) EP2285357B8 (es)
JP (1) JP5553452B2 (es)
CN (1) CN102046153B (es)
BR (1) BRPI0912161A2 (es)
CA (1) CA2722093C (es)
DK (1) DK2285357T3 (es)
ES (1) ES2465478T3 (es)
PL (1) PL2285357T3 (es)
WO (1) WO2009144286A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2563339A1 (en) 2010-04-29 2013-03-06 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
EP2618827B1 (en) * 2010-09-21 2021-06-02 Intekrin Therapeutics, Inc. Antidiabetic solid pharmaceutical compositions
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
WO2018224680A1 (en) * 2017-06-09 2018-12-13 Bimeda Research & Development Limited Intramammary veterinary composition
JP7335870B2 (ja) * 2017-08-31 2023-08-30 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形
CN109833300A (zh) * 2017-11-28 2019-06-04 浙江京新药业股份有限公司 一种抗癫痫药物口服组合物及其制备方法
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
CN111407738A (zh) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 一种布立西坦控释制剂及其制备方法
CN118267385A (zh) * 2020-07-09 2024-07-02 上海云晟研新生物科技有限公司 一种布瓦西坦药物组合物、其制备方法及应用
WO2022193723A1 (zh) * 2021-03-17 2022-09-22 长沙晶易医药科技有限公司 一种组合物及其制备方法和用途
CN115192572B (zh) * 2021-04-08 2023-09-19 成都同道慧宜生物医药科技有限公司 布立西坦药剂、其制备方法和应用
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
US12133918B2 (en) 2021-10-01 2024-11-05 Griffin Gamma, Llc Partially pre-gelatinized cassava starch as pharmaceutical excipient
TWI918738B (zh) 2021-10-14 2026-03-21 大陸商上海雲晟研新生物科技股份有限公司 布瓦西坦藥物組合物、其製備方法及應用
WO2023125348A1 (zh) * 2021-12-27 2023-07-06 广东东阳光药业有限公司 布立西坦片剂及其制备方法
CN118416004A (zh) 2023-02-02 2024-08-02 泰州越洋医药开发有限公司 一种布立西坦双释三层片及其制备方法
EP4491177A1 (en) * 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. Film coated tablets of brivaracetam
EP4491176A1 (en) * 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. A film coated tablet comprising brivaracetam
EP4559457A1 (en) * 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. A modified release tablet composition of brivaracetam
EP4559456A1 (en) * 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. A modified release tablet of brivaracetam
TR2023015501A1 (tr) * 2023-11-22 2025-06-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bri̇varasetam i̇çeren deği̇şti̇ri̇lmi̇ş salimli bi̇r tablet
TR2023015500A1 (tr) * 2023-11-22 2025-06-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bri̇varasetam i̇çeren deği̇şti̇ri̇lmi̇ş salimli bi̇r tablet kompozi̇syonu

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
AU2005325930B2 (en) * 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
WO2006090275A1 (en) * 2005-02-24 2006-08-31 Pfizer Limited Treatment of incontinence
ATE498358T1 (de) 2005-06-29 2011-03-15 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
PL1954241T3 (pl) * 2005-11-28 2013-03-29 Orexigen Therapeutics Inc Formulacja zonisamidu o przedłużonym uwalnianiu
US8338621B2 (en) * 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
CA2635949A1 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries Ltd. Controlled release formulation of divalproic acid and its derivatives
EP2041084B1 (en) * 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
JP2006335771A (ja) * 2006-09-22 2006-12-14 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
EP2081563A1 (en) * 2006-10-12 2009-07-29 Abbott Laboratories Pharmaceutical formulations

Also Published As

Publication number Publication date
US20110091547A1 (en) 2011-04-21
CN102046153B (zh) 2015-06-17
PL2285357T3 (pl) 2014-08-29
JP5553452B2 (ja) 2014-07-16
US8435564B2 (en) 2013-05-07
EP2285357B1 (en) 2014-05-07
ES2465478T3 (es) 2014-06-05
DK2285357T3 (da) 2014-06-02
CN102046153A (zh) 2011-05-04
WO2009144286A1 (en) 2009-12-03
EP2285357B8 (en) 2014-07-23
HK1153141A1 (en) 2012-03-23
CA2722093A1 (en) 2009-12-03
BRPI0912161A2 (pt) 2015-10-06
JP2011521927A (ja) 2011-07-28
CA2722093C (en) 2015-04-28
EP2285357A1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
LTPA2018014I1 (lt) Farmacinė kompozicija 514
DK2285357T3 (da) Farmaceutisk sammensætning omfattende brivaracetam
LTPA2018005I1 (lt) Farmacinė kompozicija
RU2493831C3 (ru) Фармацевтические композиции
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
BRPI0721651A2 (pt) Composição farmacêutica
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DOP2011000363A (es) Composiciones pesticidas que incluyen coadyuvantes polimericos
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2451274A4 (en) Pharmaceutical compositions
BRPI0912634A2 (pt) Composições pesticidas
DK2120884T3 (da) Farmaceutisk sammensætning
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0921654A2 (pt) formulação farmacêutica
EP2236149A4 (en) MEDICAL COMPOSITION
IT1394400B1 (it) Composizioni farmaceutiche
BRPI0921313A2 (pt) composição farmaucêutica
PT2209464E (pt) Composição farmacêutica antimalárica
BRPI0820198A2 (pt) composições farmacêuticas
BR112012014449A2 (pt) composições biocidas que compreendem derivados do ácido piroglutâmico
BRPI0912171A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas